Shares of Dechra Pharmaceuticals plc (LON:DPH) have earned an average rating of “Buy” from the eight brokerages that are currently covering the company, Marketbeat Ratings reports. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is GBX 1,784 ($23.46).
Separately, Jefferies Group LLC boosted their target price on Dechra Pharmaceuticals plc from GBX 1,565 ($20.58) to GBX 1,868 ($24.57) and gave the stock a “hold” rating in a research note on Tuesday, September 5th.
Shares of Dechra Pharmaceuticals plc (LON DPH) traded down GBX 3.43 ($0.05) during mid-day trading on Friday, reaching GBX 2,151.57 ($28.30). The company had a trading volume of 81,975 shares, compared to its average volume of 111,764. Dechra Pharmaceuticals plc has a 1 year low of GBX 1,225 ($16.11) and a 1 year high of GBX 2,199 ($28.92).
The company also recently declared a dividend, which will be paid on Friday, November 17th. Shareholders of record on Thursday, October 26th will be given a dividend of GBX 15.33 ($0.20) per share. The ex-dividend date is Thursday, October 26th. This represents a yield of 0.74%. This is a boost from Dechra Pharmaceuticals plc’s previous dividend of $6.11.
In other Dechra Pharmaceuticals plc news, insider Ian Page sold 54,910 shares of Dechra Pharmaceuticals plc stock in a transaction dated Tuesday, September 19th. The stock was sold at an average price of GBX 2,024 ($26.62), for a total transaction of £1,111,378.40 ($1,461,762.99).
WARNING: “Dechra Pharmaceuticals plc (DPH) Receives Average Rating of “Buy” from Analysts” was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2017/11/12/dechra-pharmaceuticals-plc-dph-receives-average-rating-of-buy-from-analysts.html.
About Dechra Pharmaceuticals plc
Dechra Pharmaceuticals PLC is engaged in veterinary pharmaceuticals and related products business. The Company is engaged in development, manufacture and marketing of products for veterinarians. Its segments include European Pharmaceuticals, North American (NA) Pharmaceuticals and Pharmaceuticals Research and Development.
Receive News & Ratings for Dechra Pharmaceuticals plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dechra Pharmaceuticals plc and related companies with MarketBeat.com's FREE daily email newsletter.